Cover Image
Market Research Report

Competitor Landscape: HIV

Published by GlobalData Product code 758935
Published Content info 68 Pages
Delivery time: 1-2 business days
Price
Back to Top
Competitor Landscape: HIV
Published: October 31, 2018 Content info: 68 Pages
Description

Summary

Competitor Landscape: HIV", briefings contain evaluations of ongoing development activities within the Human Immunodeficiency Virus (HIV) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report

  • Doravirine (approved in the US in Aug 2018) provides a tolerable NNRTI option with a high barrier to resistance, and is expected be used as part of multi-pill triple combinations where it may replace older NNRTIs.
  • If approved, ibalizumab would be the first biologic and first long-acting HIV drug in the EU, and would provide an option for patients with multidrug-resistant HIV infection which represents a population with a high unmet need.
  • While Frontier Biotech received China approval for albuvirtide for the treatment of HIV in Jun 2018, its FDA approved IND for a Phase II trial of albuvirtide + 3BNC117 is the first indication of clinical activity in the US.
Competitor Landscape: Human Immunodeficiency Virus (HIV) report comprises five key sections. Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted the HIV landscape.

Landscape Updates

  • 'Order of Entry' analysis, detailing timeline forecasts for each drug in Phase II development or higher.
  • Timeline forecasts for each approved product's lifecycle management initiatives.
  • 'Market Entry' & 'Direction of Travel' positioning analysis for pipeline & currently approved therapies.

Pipeline Landscape

  • An overview of pipeline candidates, containing snapshots of current development status.
  • Expected drug-specific events & milestones until YE 2021.
Approved Product Landscape: An overview of approved drugs, containing snapshots of current development status.

Appendix

  • Current early stage HIV pipeline & candidate 'Watch List'.
  • Timeline assumptions, including standard assumptions & drug-specific assumptions.

Scope

  • The briefing is based on Sociable Pharma's analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • 'Market Entry' & 'Direction of Travel' positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents
Product Code: GDHC073SP

Table of Contents

Introduction to Sociable Pharma's HIV 'Competitor Landscape'

Executive Summary

  • Key Events & Landscape Updates
  • Updated Milestones

Landscape Updates

  • Order of Entry
  • Key Competitor Market Entry Strategies
  • Lifecycle Development
  • Key Competitor 'Direction of Travel'

Pipeline Landscape

  • Pipeline Summary
  • Events & Milestones: 2018-19

Approved Product Development Landscape

  • Lifecycle Development

Appendix

Back to Top